Primary Disease: Unresectable or Metastatic Renal Cell Carcinoma Focus of the Study:PFS Assessed by IRC Per RECIST 1.1
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Study to Evaluate the Efficacy and Safety of Toripalimab in Combination With Axitinib Versus Sunitinib Monotherapy in Advanced Renal Cell Cancer (NCT04394975) | Shanghai Junshi Bioscience Co., Ltd. | 2020-08-20 |
Track Primary Disease: Unresectable or Metastatic Renal Cell Carcinoma Focus of the Study:PFS Assessed by IRC Per RECIST 1.1 automatically
Every clearance here is in the API, with alerts when new ones post.